Please call Clinical Labs of Hawaii at 808.677.7998 (Option 1) with questions about this test.
Synonyms
CA 27.29
MAM 6
Milk Mucin
Breast Cancer Tumor Markers
Breast Carcinoma-Associated Antigen (CA 27.29), Serum
CA 27-29
CA2729 80392, Breast Cancer Tumor Markers, Breast Carcinoma-Associated Antigen (CA 27.29) serum, MAM 6, Milk Mucin
Collect
Plain red or serum separator tube or EDTA plasma.
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Stability (from collection to initiation)
After separation from cells: Ambient: 8 hours; Refrigerated: 7 days; Frozen: 3 months
Storage/Transport Temperature
Frozen.
Performed
Sun-Sat
Reported
Within 24 hours
Methodology
Quantitative Chemiluminescent Immunoassay
Test Site
ARUP (80392)
Reference Interval
Effective August 16, 2021 Less than or equal to 39 U/mL
Interpretive Data
Test Information: The CA 27.29 assay is intended for use in monitoring: 1) disease progression and/or response to therapy in patients with metastatic disease, and 2) disease recurrence in patients treated previously for stages II or III breast carcinoma who are clinically free of the disease. Serial testing in patients who are clinically free of disease should be used in conjunction with other clinical methods for early detection of cancer recurrence.
Limitations: Patients with confirmed breast carcinoma frequently have CA 27.29 assay values in the same range as healthy individuals. Elevations may also be observed in patients with non-malignant disease. Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy.
Methodology: Siemens Atellica IM BR 27.29 (BR) chemiluminescent immunoassay was used. Results obtained with different assay methods or kits cannot be used interchangeably.
CPT Codes
86300
LOINC
17842-6
Collect
Plain red or serum separator tube or EDTA plasma.
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Storage/Transport Temperature
Frozen.
Stability (from collection to initiation)
After separation from cells: Ambient: 8 hours; Refrigerated: 7 days; Frozen: 3 months
Interpretive Data
Test Information: The CA 27.29 assay is intended for use in monitoring: 1) disease progression and/or response to therapy in patients with metastatic disease, and 2) disease recurrence in patients treated previously for stages II or III breast carcinoma who are clinically free of the disease. Serial testing in patients who are clinically free of disease should be used in conjunction with other clinical methods for early detection of cancer recurrence.
Limitations: Patients with confirmed breast carcinoma frequently have CA 27.29 assay values in the same range as healthy individuals. Elevations may also be observed in patients with non-malignant disease. Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy.
Methodology: Siemens Atellica IM BR 27.29 (BR) chemiluminescent immunoassay was used. Results obtained with different assay methods or kits cannot be used interchangeably.
LOINC
17842-6
Synonyms
CA 27.29
MAM 6
Milk Mucin
Breast Cancer Tumor Markers
Breast Carcinoma-Associated Antigen (CA 27.29), Serum
CA 27-29
CA2729 80392, Breast Cancer Tumor Markers, Breast Carcinoma-Associated Antigen (CA 27.29) serum, MAM 6, Milk Mucin
Effective August 16, 2021 Less than or equal to 39 U/mL
Test Site
ARUP (80392)
Summary
Test Code
CA2729
Ordering Code
6877
Questions?
Please call Clinical Labs of Hawaii at 808.677.7998 (Option 1) with questions about this test.
Synonyms
CA 27.29
MAM 6
Milk Mucin
Breast Cancer Tumor Markers
Breast Carcinoma-Associated Antigen (CA 27.29), Serum
CA 27-29
CA2729 80392, Breast Cancer Tumor Markers, Breast Carcinoma-Associated Antigen (CA 27.29) serum, MAM 6, Milk Mucin
Collect
Plain red or serum separator tube or EDTA plasma.
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Stability (from collection to initiation)
After separation from cells: Ambient: 8 hours; Refrigerated: 7 days; Frozen: 3 months
Storage/Transport Temperature
Frozen.
Performed
Sun-Sat
Reported
Within 24 hours
Methodology
Quantitative Chemiluminescent Immunoassay
Test Site
ARUP (80392)
Reference Interval
Effective August 16, 2021 Less than or equal to 39 U/mL
Interpretive Data
Test Information: The CA 27.29 assay is intended for use in monitoring: 1) disease progression and/or response to therapy in patients with metastatic disease, and 2) disease recurrence in patients treated previously for stages II or III breast carcinoma who are clinically free of the disease. Serial testing in patients who are clinically free of disease should be used in conjunction with other clinical methods for early detection of cancer recurrence.
Limitations: Patients with confirmed breast carcinoma frequently have CA 27.29 assay values in the same range as healthy individuals. Elevations may also be observed in patients with non-malignant disease. Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy.
Methodology: Siemens Atellica IM BR 27.29 (BR) chemiluminescent immunoassay was used. Results obtained with different assay methods or kits cannot be used interchangeably.
CPT Codes
86300
LOINC
17842-6
Collection
Collect
Plain red or serum separator tube or EDTA plasma.
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Storage/Transport Temperature
Frozen.
Stability (from collection to initiation)
After separation from cells: Ambient: 8 hours; Refrigerated: 7 days; Frozen: 3 months
Interpretive Data
Test Information: The CA 27.29 assay is intended for use in monitoring: 1) disease progression and/or response to therapy in patients with metastatic disease, and 2) disease recurrence in patients treated previously for stages II or III breast carcinoma who are clinically free of the disease. Serial testing in patients who are clinically free of disease should be used in conjunction with other clinical methods for early detection of cancer recurrence.
Limitations: Patients with confirmed breast carcinoma frequently have CA 27.29 assay values in the same range as healthy individuals. Elevations may also be observed in patients with non-malignant disease. Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy.
Methodology: Siemens Atellica IM BR 27.29 (BR) chemiluminescent immunoassay was used. Results obtained with different assay methods or kits cannot be used interchangeably.
Administrative
LOINC
17842-6
Synonyms
CA 27.29
MAM 6
Milk Mucin
Breast Cancer Tumor Markers
Breast Carcinoma-Associated Antigen (CA 27.29), Serum
CA 27-29
CA2729 80392, Breast Cancer Tumor Markers, Breast Carcinoma-Associated Antigen (CA 27.29) serum, MAM 6, Milk Mucin